Lidanserin

File:Lidanserin structure.png

thumb

Lidanserin (INN; ZK-33,839) is a serotonergic and adrenergic receptor antagonist developed for the treatment of hypertension. It acts as a dual antagonist at the 5-HT_2A and α₁-adrenergic receptors, making it pharmacologically similar to ketanserin.

Pharmacology

Lidanserin exerts its effects by blocking key receptors involved in vasoconstriction and platelet aggregation, leading to vasodilation and blood pressure reduction. Its primary actions include:

• 5-HT_2A receptor antagonism – Reduces vascular smooth muscle contraction, preventing serotonin-induced vasoconstriction.
• α₁-adrenergic receptor antagonism – Lowers peripheral vascular resistance by inhibiting norepinephrine-induced vasoconstriction.

These mechanisms suggest its potential as an antihypertensive agent, but it was never marketed.

Potential Clinical Uses

Although not commercially available, Lidanserin was investigated for:

• Hypertension – As a vasodilator to lower blood pressure.
• Thrombosis prevention – Due to its anti-platelet effects.
• Vascular disorders – Such as Raynaud’s phenomenon and migraine prophylaxis, owing to its serotonergic modulation.

Comparison to Ketanserin

Lidanserin shares pharmacological similarities with ketanserin, another 5-HT_2A and α₁-adrenergic antagonist, which was approved for hypertension treatment in some regions. However, Lidanserin never progressed beyond clinical trials.

Chemical Structure

Lidanserin belongs to several chemical classes:

• Piperidine derivatives – Contributing to receptor binding affinity.
• Pyrrolidone structure – Involved in metabolic stability.
• Organofluoride compounds – Modifying lipophilicity and receptor interactions.

See also

• Ketanserin
• Serotonin receptor antagonists
• Alpha blockers
• Antihypertensive agents

Antihypertensive agents